CD30 expression in a case of intravascular large B‐cell lymphoma, cutaneous variant

Provasi, Matteo; Bagnoli, Filippo; Fanoni, Daniele; Alberti‐Violetti, Silvia; Tomasini, Dario; Berti, Emilio

doi:10.1111/cup.13446

Cited by 8 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the immunoblasts of ILVIP express polytypic light chains. CD30 is also helpful as it is often negative in cases of IV-LBCL 27 but was positive in most ILVIP cases in this study.…”

Section: Ilvips Composed Of Large Cells Within Blood Vessels or Sinus...mentioning

confidence: 65%

Reactive Intralymphovascular Immunoblastic Proliferations Mimicking Aggressive Lymphomas

Fang

Wang

Zhang

et al. 2021

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Reactive intralymphovascular immunoblastic proliferations (ILVIPs) may mimic aggressive lymphomas and are rarely reported. Herein, we characterize the clinicopathologic features of 8 patients with ILVIPs. No patients had lymphadenopathy, hepatosplenomegaly, or other findings suggestive of lymphoma. The ILVIPs involved the small or large intestine (n=5) and appendix (n=3). Patients were evaluated for abdominal pain, suspected appendicitis, intestinal obstruction, diverticulitis, volvulus, or tumor resection. Histologic sections showed expanded lymphovascular spaces filled by intermediate to large immunoblasts, positive for CD38, CD43, CD45, CD79a, and MUM1/IRF4 in all cases tested. Five of 6 (83%) cases were positive for CD30. CD20 was weakly positive in a subset of cells in 2 (25%) cases, and PAX5 was weakly positive in 4 (50%) cases. The immunoblasts expressed polytypic light chains in all cases tested. In 1 case, a subset of immunoblasts expressed T-cell markers indicating the presence of a T-cell component. The immunoblasts were negative for ALK, BCL-2, BCL-6, CD10, CD56, CD138, and Epstein-Barr virus–encoded small RNA in all cases assessed. The proliferation index shown by Ki-67 was high with a median of 80%. In all 6 cases tested, the immunoblasts were shown within lymphatic channels highlighted by D2-40. In conclusion, ILVIPs can be rarely observed in patients with inflammatory or infectious conditions, especially in gastrointestinal tract surgical specimens. The immunoblasts are predominantly of B-lineage with a postgerminal center immunophenotype and are located within lymphatic channels. It is essential to distinguish reactive ILVIPs from aggressive lymphomas to avoid unnecessary therapy.

show abstract

Section: Ilvips Composed Of Large Cells Within Blood Vessels or Sinus...mentioning

confidence: 65%

Reactive Intralymphovascular Immunoblastic Proliferations Mimicking Aggressive Lymphomas

Fang

Wang

Zhang

et al. 2021

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…The literature includes 11 studies that examined CD30 expression in primary cutaneous B‐cell lymphomas (pcBCL), with a total of 48 patients (Table 5). 33,34,104‐111 CD30 positivity was found in three primary cutaneous follicle center lymphoma (pcFCL) studies with eight patients (including two CD30‐negative cases), 33,34,104 one primary cutaneous marginal zone B‐cell lymphoma (pcMZL) study with 22 patients, 105 four DLBCL studies with 13 patients 106‐109 and a case report of a patient with primary cutaneous intravascular large B‐cell lymphoma (pcIVLBCL) 112 . Two studies with four DLBCL (leg type) patients were CD30‐negative 110,111 .…”

Section: Resultsmentioning

confidence: 99%

“…Some reports of CD30 expression in DLBCL were described (totally 13 patients), 106‐109 while in four cases of DLBCL leg type all cases are CD30‐negative 110,111 . Only one case of IVLBCL showed CD30‐positive cells after relapse 112 …”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

A review ofCD30expression in cutaneous neoplasms

Kampa

Mitteldorf

2020

J Cutan Pathol

View full text Add to dashboard Cite

Background: The surface protein CD30 is a therapeutic target of monoclonal antibody therapy. Knowledge of the frequency of CD30 expression and its prognostic relevance is therefore interesting, not only in lymphoproliferative disorders (LPD) but also in solid tumors of the skin. Methods: A review was completed in PubMed for all published reports of CD30 expression in cutaneous lymphomas, mastocytosis, epithelial tumors and sarcomas from 1982 to April 2019. Only accessible articles in English and German were considered. Entities with an expected CD30 expression, such as CD30-positive LPD, were not evaluated. Results: The electronic research identified 1091 articles and a further 34 articles were obtained from manual bibliographic reference. Overall 91 articles were included that examined CD30 expression in various entities of cutaneous neoplasms and matched the inclusion criteria. Conclusion: Apart from cutaneous CD30-positive LPD, the best-studied group for CD30 expression was mycosis fungoides (MF). CD30 positivity was found in 32% of classical (patch and plaque stage) and in 59.4% cases of transformed MF. CD30 was also frequently expressed in cutaneous mastocytosis (96.5%). In solid tumors, some single reports describe CD30 expression by tumor cells, but CD30-reactive lymphocytes were frequently observed in the tumor microenvironment (TME), especially in keratoacanthoma (KA).

show abstract

“…4,14 Expression of uncommon markers such as myeloperoxidase and CD30 have also been described. [19][20][21] Ki-67 proliferation indices are frequently high, with expression above 50% in most cases (Table ). 6,21,22 One small case series explored programmed death-ligand 1 (PD-L1) immunoexpression, noting that a subset of IVLBCL cases were highlighted by this marker (45.4%, of n ¼ 11), with potential implications for targeted therapy.…”

Section: Epidemiology Clinical Presentation Andmentioning

confidence: 99%

Intravascular Large B-Cell Lymphoma

Davis

Auerbach

Crothers

et al. 2022

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Intravascular large B-cell lymphoma (IVLBCL) is a rare hematopathologic entity, posing both a clinical and histologic challenge for diagnosis. Numerous pitfalls can hinder making the diagnosis. Objective.— To summarize recent developments in literature pertaining to IVLBCL and point out key pitfalls pathologists should be prepared to encounter. Data Sources.— Literature review via PubMed search and hospital (Darnall Medical Library) resources. Conclusions.— The 3 primary pitfalls of IVLBCL include masking of IVLBCL, mimicry by IVLBCL, and mimicry of IVLBCL. These scenarios illustrate the importance of histologic pattern recognition and subsequent usage of immunohistochemistry, especially in context of a clinical history that may be noncharacteristic.

show abstract

CD30 expression in a case of intravascular large B‐cell lymphoma, cutaneous variant

Abstract: E. CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant.

Cited by 8 publications

References 25 publications

Reactive Intralymphovascular Immunoblastic Proliferations Mimicking Aggressive Lymphomas

Reactive Intralymphovascular Immunoblastic Proliferations Mimicking Aggressive Lymphomas

A review ofCD30expression in cutaneous neoplasms

Intravascular Large B-Cell Lymphoma

Contact Info

Product

Resources

About